Novel targets for parkinsonism-depression comorbidity
With the aging population growing and the incidence of neurodegenerative diseases on the rise, the researchers in the field are yet more urgently challenged to slow and/or reverse the devastating consequences of such progression. The challenge is further enforced by psychiatric co-morbid conditions, particularly the feeling of despair in these population. Fortunately, as our understanding of the neurobiological substrates of maladies affecting the central nervous system increases, more therapeutic options are also presented. In this short review while providing evidence of shared biological substrates between Parkinson's disease and depression, novel therapeutic targets and drugs are suggested. The emphasis will be on neuroplasticity underscored by roles of neurotrophic and inflammatory factors. Examples of few therapeutic drugs as well as future directions are also touched upon.
Tizabi, Yousef; Getachew, Bruk; Csoka, Antonei B.; Manaye, Kebreten F.; and Copeland, Robert L., "Novel targets for parkinsonism-depression comorbidity" (2019). College of Medicine Faculty Publications. 357.